Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421

Children's Oncology Group

Status: Completed

Conditions: Leukemia

Treatments: Genetic: gene expression analysis; Genetic: microarray analysis; Other: laboratory biomarker analysis; Genetic: proteomic profiling

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01035307

AAML09B2

CDR0000659560 (Other Identifier)

COG-AAML09B2 (Other Identifier)

NCI-2011-02201 (Registry Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at biomarkers in tissue samples from young patients with acute myeloid leukemia previously enrolled on clinical trial POG-9421.

Full description

OBJECTIVES:

• To profile basal and potentiated phospho-protein networks (PPPNs) using tissue samples from pediatric patients with de novo acute myeloid leukemia (AML) previously enrolled on clinical trial POG-9421.
• To classify AML-based signal transduction mechanisms.
• To correlate profiles of basal and PPPNs with specific molecular lesions (e.g., FLT3-ITD, NPM, WT1, c-kit, CEPBα, PASGΔ75, and karyotype) and profiles of gene expression in tumor tissue samples.

OUTLINE: Banked tissue samples are collected for laboratory studies, including phospho-protein signaling and gene expression profiling studies.

Enrollment: 90 estimated patients

Sex: All

Ages: Under 20 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Diagnosis of acute myeloid leukemia, meeting 1 of the following criteria:

  • Primary induction failure (i.e., failed to achieve remission within the first 60 days of therapy)
  • Relapsed disease (early or late)
  • In continuous complete remission

• Previously enrolled on POG-9421

• Tissue samples available

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

Trial design

90 participants in 1 patient group

Genomic and Proteomic Profiling

Treatment:

Genetic: proteomic profiling

Genetic: microarray analysis

Genetic: gene expression analysis

Other: laboratory biomarker analysis